Femasys Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FEMY research report →
Companywww.femasys.com
Femasys Inc. , a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.
- CEO
- Kathy Lee-Sepsick
- IPO
- 2021
- Employees
- 69
- HQ
- Suwanee, GA, US
Price Chart
Valuation
- Market Cap
- $10.34M
- P/E
- -1.89
- P/S
- 4.35
- P/B
- 3.21
- EV/EBITDA
- -0.66
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 53.12%
- Op Margin
- -687.93%
- Net Margin
- -521.78%
- ROE
- -258.08%
- ROIC
- -118.32%
Growth & Income
- Revenue
- $2.29M · 40.77%
- Net Income
- $-18,627,887 · 1.00%
- EPS
- $-0.47 · 44.05%
- Op Income
- $-17,588,669
- FCF YoY
- 4.90%
Performance & Tape
- 52W High
- $1.11
- 52W Low
- $0.31
- 50D MA
- $0.44
- 200D MA
- $0.59
- Beta
- -2.25
- Avg Volume
- 508.26K
Get TickerSpark's AI analysis on FEMY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 30, 26 | Canning John Charles | other | 150,000 |
| Mar 30, 26 | Canning John Charles | other | 0 |
| Mar 19, 26 | Lee-Sepsick Kathy | other | 68,244 |
| Mar 19, 26 | Elefant Dov | other | 34,122 |
| Mar 19, 26 | Eichenbaum Kenneth D. | other | 102,366 |
| Mar 19, 26 | Larsen Charles | other | 34,122 |
| Mar 18, 26 | Eichenbaum Kenneth D. | other | 0 |
| Nov 7, 25 | Eichenbaum Kenneth D. | other | 102,366 |
| Nov 7, 25 | Eichenbaum Kenneth D. | other | 102,366 |
| Nov 7, 25 | Eichenbaum Kenneth D. | other | 102,366 |
Our FEMY Coverage
We haven't published any research on FEMY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FEMY Report →